
|Podcasts|April 28, 2022
Diabetes Dialogue: April 2022 Edition
In the April 2022 edition of Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives, hosts Drs. Diana Isaacs and Natalie Bellini discuss the implications of the FDA's approval of semaglutide 2.0 mg, the use of novel glycemic control metrics, and a preview of ATTD 2022.
Advertisement
Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives is available in an audio-only format on
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
The HCPFive: Top News for Healthcare Providers from the Week of 07/12
2
Millions of New Patients Eligible for Statins Under 2026 AHA/ACC Guidelines
3
Sonnenberg Breaks Down EMERGE Phase 3 Trial Design for DT120 in MDD
4
FDA Expands Exa-Cel (Casgevy) Approval, Bringing Gene Therapy to Younger Children
5










































































